Skip to main content
Premium Trial:

Request an Annual Quote

ExoDx Prostate (IntelliScore)

Exosome Diagnostics has launched its ExoDx Prostate (IntelliScore), a laboratory-developed test designed to provide clinicians and patients with information to improve the prostate biopsy decision-making process. The test is urine-based, and analyzes samples for three biomarkers on exosomal RNA that are expressed in men with high-grade prostate cancer. It assigns an individual risk score from zero to 100 using an algorithm that combines the relative weighted expression of the three-gene-signature, the company said. 

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.